5-Bromo-4-ethoxy-2-((4-methoxybenzyl)oxy)pyridine, 97%, 100mg

Acide 5-méthylsalicylique, min 98 %, pour la synthèse, 25 g, emballage plastique.

1-(2-Fluoro-4-nitro-phenyl)-4-methyl-piperidine, 5g

(S)-3-Amino-3-(2-bromophenyl)propanoic acid, 95.0%, 10g

8-Benzyl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one, 97.0%, 1g

5-amino-2-(tetrahydro-2-furanylmethyl)-1H-isoindole-1,3(2H)-dione, 95.0%, 1g

2-[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]acetonitrile, 97%, 25g

Methyl 2-bromofuran-3-carboxylate, 95.0%, 10g

3-(2-Aminoethylamino)propyltriethoxysilane, 99.00%, 25g

ETHYL 7-(TRIFLUOROMETHYL)IMIDAZO[1,2-A]PYRIDINE-3-CARBOXYLATE, 95.0%, 100mg

2-(4-Methylpyridin-2-yl)acetonitrile, 95+%, 100mg

(4,4'-Di-tert-butyl-2,2'-bipyridine)bis[3,5-difluoro-2-[5-trifluoromethyl-2-pyridinyl-kappaN)phenyl-kappaC]iridium(III) Hexafluorophosphate>95.0%(HPLC)(qNMR)1g

3-Amino-4-fluorobenzonitrile, 95.0%, 1g